Table 6. Company-Level Distribution of All Payments and R&D Payments in Belgium, Ireland, and the United Kingdom (2017-2019) .
| UK | Belgium | Ireland | |||||||
| R&D Payments (€) | All Payments (€) | R&D Payments as % All Payments | R&D Payments (€) | All Payments (€) | % R&D Payments | R&D Payments (€) | All Payments (€) | % R&D Payments | |
| Median (IQR) | 295 089 (0–3 188 268) | 1 338 212 (210 583–7 233 079) |
32.8% (0%–68%) | 0% (0%–0%) | 60 448 (13 205–342 131) |
0% (0%–0%) | 195 861 (0 –1 482 405) |
953 706 (261 021 –2 453 010) |
27% (0%–47%) |
| Maximum | 167 143 325 | 183 036 733 | 100% | 55 238 184 | 69 381 760 | 98% | 15 877 914 | 15 951 700 | 100% |
| Gini Index | 0.86 | 0.82 | 0.96 | 0.91 | 0.76 | 0.63 | |||
| Top 10 donor share | 66% | 60% | 71% | 55% | 82% | 70% | |||
| Top 20 donor share | 86% | 81% | 90% | 74% | 97% | 89% | |||
| Top 10 donor share within global Top 20 largest companies | 100% | 100% | 90% | 90% | 90% | 90% | |||
| Top 20 donor share within global Top 20 largest companies | 80% | 85% | 75% | 75% | 75% | 75% | |||
Abbreviations: R&D, Research and Development; IQR, interquartile range.
Notes. The R&D payment data reported in this table was extracted from eurosfordocs.eu.86
The company size data (the top 20 companies) was calculated using three combined yearly rankings of the top 50 largest companies based on global sales values published Pharmaceutical Executive.96-98 The years covered by the sales rankings corresponded with the years in which the payment disclosures were made.